Clinical Trial Update: A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719 [NA]

View source ↗

Summary

A completed window-of-opportunity trial in head and neck squamous cell carcinoma evaluated biomarker modulation after preoperative BYL719 (alpelisib) treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• BYL719 (alpelisib)

Snippet

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Conditions: Head and Neck Squamous Cell Cancer | NA | Status: COMPLETED